Drugs / MHB036C
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06373406 | May 2023 → Dec 2025 overdue | neoplasm | Minghui Pharmaceutical (Hangzhou) Ltd | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05642949 | Jan 2023 → Dec 2025 | neoplastic disease or syndrome | Minghui Pharmaceutical Pty Ltd | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07130383 | Sep 2025 → Aug 2029 expected | female breast carcinoma | Minghui Pharmaceutical (Hangzhou) Ltd | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MHB036C | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07130383 ↗ |
| Modality | Other / unclassified | “An antibody-drug conjugate therapy” NCT06373406 ↗ |
| Route | Intravenous | “MHB036C will be administered intravenously at a frequency of once every 3 weeks (Q3W).” NCT05642949 ↗ |